Literature DB >> 26155411

γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?

Jaydeep Bhat1, Dieter Kabelitz1.   

Abstract

γδ T cell-based immunotherapeutic strategies in cancer patients are as yet of limited success. Drugs targeting epigenetic mechanisms including histone acetylation and DNA methylation trigger cell death in tumor cells but in addition have immunomodulatory activity. Here, we discuss the potential benefit of combining both strategies in cancer immunotherapy.

Entities:  

Keywords:  DNMTi, DNA methyltransferase inhibitor(s); HDACi, histone deacetylase inhibitor(s); IL-2, interleukin-2; N-BP, nitrogen-containing bisphosphonate; NKG2D, natural killer group 2 member D; NSCLC, non-small cell lung cancer; epigenetic drugs; histone deacetylase inhibitor; immunotherapy; tumor cell; γδ T cells

Year:  2015        PMID： 26155411      PMCID： PMC4485805          DOI： 10.1080/2162402X.2015.1006088

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  64 in total

1.  Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.

Authors:  A Baragaño Raneros; V Martín-Palanco; A F Fernandez; R M Rodriguez; M F Fraga; C Lopez-Larrea; B Suarez-Alvarez
Journal:  Genes Immun       Date:  2014-11-13       Impact factor: 2.676

2.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

3.  Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.

Authors:  Seiko Iwata; Takashi Saito; Yoshinori Ito; Maki Kamakura; Kensei Gotoh; Jun-Ichi Kawada; Yukihiro Nishiyama; Hiroshi Kimura
Journal:  Cancer Sci       Date:  2011-11-22       Impact factor: 6.716

Review 4.  Regulation of mevalonate metabolism in cancer and immune cells.

Authors:  Martin Thurnher; Georg Gruenbacher; Oliver Nussbaumer
Journal:  Biochim Biophys Acta       Date:  2013-03-21

5.  A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy.

Authors:  Sunil Sharma; James Symanowski; Bryan Wong; Pamela Dino; Phillip Manno; Nicholas Vogelzang
Journal:  Transl Oncol       Date:  2008-09       Impact factor: 4.243

6.  Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.

Authors:  N Kato; J Tanaka; J Sugita; T Toubai; Y Miura; M Ibata; Y Syono; S Ota; T Kondo; M Asaka; M Imamura
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

7.  Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.

Authors:  Metin Karahoca; Richard L Momparler
Journal:  Clin Epigenetics       Date:  2013-02-01       Impact factor: 6.551

8.  Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2'-deoxycytidine).

Authors:  Richard L Momparler
Journal:  Front Oncol       Date:  2013-07-29       Impact factor: 6.244

9.  Genome-wide methylation analyses of primary human leukocyte subsets identifies functionally important cell-type-specific hypomethylated regions.

Authors:  Matthias Zilbauer; Tim F Rayner; Christine Clark; Alison J Coffey; Chris J Joyce; Priit Palta; Aarno Palotie; Paul A Lyons; Kenneth G C Smith
Journal:  Blood       Date:  2013-10-24       Impact factor: 22.113

10.  Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells.

Authors:  Matilde Todaro; Serena Meraviglia; Nadia Caccamo; Giorgio Stassi; Francesco Dieli
Journal:  Oncoimmunology       Date:  2013-07-29       Impact factor: 8.110
View more
  14 in total

1.  Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.

Authors:  Maria Raffaella Zocchi; Delfina Costa; Roberta Venè; Francesca Tosetti; Nicoletta Ferrari; Simona Minghelli; Roberto Benelli; Stefano Scabini; Emanuele Romairone; Silvia Catellani; Aldo Profumo; Alessandro Poggi
Journal:  Oncoimmunology       Date:  2017-01-06       Impact factor: 8.110

2.  Analysis of tumor-infiltrating gamma delta T cells in rectal cancer.

Authors:  Liang Rong; Ke Li; Rui Li; Hui-Min Liu; Rui Sun; Xiao-Yan Liu
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

3.  Immunosuppressive γδ T cells foster pancreatic carcinogenesis.

Authors:  Laura Mondragón; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-09-27       Impact factor: 8.110

4.  Expression of non-secreted IL-4 is associated with HDAC inhibitor-induced cell death, histone acetylation and c-Jun regulation in human gamma/delta T-cells.

Authors:  Jaydeep Bhat; Justyna Sosna; Jürgen Fritsch; Elgar Susanne Quabius; Stefan Schütze; Sebastian Zeissig; Ole Ammerpohl; Dieter Adam; Dieter Kabelitz
Journal:  Oncotarget       Date:  2016-10-04

5.  Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors.

Authors:  Zhaoxu Li; Junzhe Zhang; Jicun Tang; Ruiying Wang
Journal:  Oncotarget       Date:  2016-12-20

6.  Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates.

Authors:  Shengdong Wang; Hengyuan Li; Chenyi Ye; Peng Lin; Binghao Li; Wei Zhang; Lingling Sun; Zhan Wang; Deting Xue; Wangsiyuan Teng; Xingzhi Zhou; Nong Lin; Zhaoming Ye
Journal:  Front Immunol       Date:  2018-02-27       Impact factor: 7.561

7.  Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis.

Authors:  Zhan Wang; Zenan Wang; Shu Li; Binghao Li; Lingling Sun; Hengyuan Li; Peng Lin; Shengdong Wang; Wangsiyuan Teng; Xingzhi Zhou; Zhaoming Ye
Journal:  Front Immunol       Date:  2018-06-01       Impact factor: 7.561

8.  Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells.

Authors:  Heleen H Van Acker; Sébastien Anguille; Yannick Willemen; Johan M Van den Bergh; Zwi N Berneman; Eva Lion; Evelien L Smits; Viggo F Van Tendeloo
Journal:  J Hematol Oncol       Date:  2016-09-29       Impact factor: 17.388

Review 9.  Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.

Authors:  Timm Hoeres; Manfred Smetak; Dominik Pretscher; Martin Wilhelm
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

10.  Overexpression of miR-382 Sensitizes Hepatocellular Carcinoma Cells to γδ T Cells by Inhibiting the Expression of c-FLIP.

Authors:  Zhong Chen; Zhiang Zheng; Lan Feng; Zhenqing Huo; Liju Huang; Mingchang Fu; Qiuzan Chen; YanZhuang Ke; Jinjun Yang; Benxin Hou
Journal:  Mol Ther Oncolytics       Date:  2020-07-31       Impact factor: 7.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.